Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSNNASDAQ:MACKNASDAQ:MREONASDAQ:NRBONASDAQ:VBLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AMREOMereo BioPharma Group$2.88+0.2%$2.55$1.58▼$5.02$456.33M0.461.09 million shs799,203 shsNRBONeuroBo Pharmaceuticals$0.65-2.1%$0.71$2.08▼$5.16$5.58M-0.2639,197 shs48,968 shsVBLTVascular Biogenics$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%MACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MREOMereo BioPharma Group0.00%+8.08%+12.75%+44.47%-19.92%NRBONeuroBo Pharmaceuticals-2.10%-4.72%-3.56%-55.62%-85.51%VBLTVascular Biogenics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMREOMereo BioPharma Group1.9659 of 5 stars3.63.00.00.00.61.70.0NRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunon 0.00N/AN/AN/AMACKMerrimack Pharmaceuticals 0.00N/AN/AN/AMREOMereo BioPharma Group 3.20Buy$7.60164.35% UpsideNRBONeuroBo Pharmaceuticals 0.00N/AN/AN/AVBLTVascular Biogenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLSN, MREO, MACK, VBLT, and NRBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMREOMereo BioPharma Group$10M45.71N/AN/A$0.39 per share7.37NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/AVBLTVascular Biogenics$660K0.00N/AN/A$0.32 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AMACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/AMREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/ALatest CLSN, MREO, MACK, VBLT, and NRBO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52MACKMerrimack PharmaceuticalsN/A10.7810.78MREOMereo BioPharma GroupN/A8.928.92NRBONeuroBo PharmaceuticalsN/A2.412.41VBLTVascular BiogenicsN/A4.634.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%MACKMerrimack Pharmaceuticals63.97%MREOMereo BioPharma Group62.83%NRBONeuroBo Pharmaceuticals1.37%VBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%MACKMerrimack Pharmaceuticals30.57%MREOMereo BioPharma Group5.50%NRBONeuroBo Pharmaceuticals1.05%VBLTVascular Biogenics6.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableCLSN, MREO, MACK, VBLT, and NRBO HeadlinesRecent News About These CompaniesVBL warns of financial impact of severance payments in second pillar reformSeptember 4, 2024 | ipe.comIMarket Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%July 30, 2024 | msn.comTom Sox move one step closer to VBL title with 7-5 win over PurcellvilleJuly 30, 2024 | cbs19news.comCTom Sox drop game one of the VBL South Division Series against Cavaliers, 4-1July 26, 2024 | cbs19news.comCBenign and Malignant Vascular Tumors of the Liver in AdultsMay 23, 2024 | medscape.comMVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeMay 14, 2024 | msn.comAlboGraft Polyester Vascular Graft from LeMaitreMay 7, 2024 | news-medical.netNTommy Garten elected to VBL Hall of FameMarch 28, 2024 | therecorderonline.comTControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemFebruary 21, 2024 | nature.comNVascular News and ResearchNovember 25, 2023 | news-medical.netNVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26November 2, 2023 | msn.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 9, 2023 | finance.yahoo.comVBLT Stock Sees Decline of Approximately -0.22% in Last Five DaysSeptember 7, 2023 | knoxdaily.comKVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECSeptember 6, 2023 | finance.yahoo.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comMedia Sentiment Over TimeCLSN, MREO, MACK, VBLT, and NRBO Company DescriptionsImunon NASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Merrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Mereo BioPharma Group NASDAQ:MREO$2.88 +0.01 (+0.17%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.65 -0.01 (-2.10%) As of 07/3/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Vascular Biogenics NASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.